|
ELISA
|
Anti-BACE1 Ab SECB1&2 [56, 57]
|
Synthetic peptide substrates containing the β-cleavage site (Calbiochem, EMD, Gibbstown, NJ, USA) [59]
|
Shen et al. [36]
|
Plasma BACE1 activity significantly increased by 53.2% in MCI and by 68.9% in AD compared to HC
|
|
ELISA
|
Anti-BACE1 Ab SECB1&2 [56, 57]
|
Synthetic substate-C-terminally labeled with the fluorescent, Luciferase Yellow, and N-terminally labeled with the quenching, Dabsyl
|
Cervellati et al. [35]
|
Increased BACE1 activity in serum of AD
|
|
ELISA
|
Biotinylated detector mAb, diluted in a buffer adapted for the plasma matrix
|
Kit-based assay EQ 6541–9601-L; Euroimmun AG, Lübeck, Germany [18]
|
Vergallo et al. [37]
|
Plasma BACE1 significantly higher in women than in men in cognitively healthy individuals at clinical risk for AD
|
|
Solution-based platelet BACE1 assay
| |
Fluorogenic substrate (Calbiochem, BACE1 substrate I)
|
Johnston et al. [39]
|
17% increase in platelet membrane BACE1 activity in AD compared to HC
|
|
Solution-based platelet BACE1 assay
| |
Fluorescence-quenching substrate (Calbiochem, Merck, Darmstadt, Germany)
|
Bermejo-Bescós et al. 2013 [40]
|
No significant difference in BACE1 activity between MCI and HC
|
|
Solution-based platelet BACE1 assay
| |
Fluorogenic substrate (Sigma A1472 or Bachem M2465)
|
Wongchitrat et al. [44]
|
Baseline platelet membrane BACE1 activity not significantly different between MCI vs HC
|
|
Immunoassay
| |
Immunoassay kit (CUSABIO, USA)
|
Vakilian et al. [45]
|
Elevated plasma levels of BACE1 in AD vs HC
|
|
RNA expression analysis
| |
Real-time quantitative RT-PCR
|
Ghafouri-Fard et al. [50]
|
BACE1 levels significantly high in bipolar disorder
|
|
RNA expression analysis
| |
Real-time quantitative RT-PCR
|
Nafisi-Far et al. [51]
|
BACE1 levels significantly high in schizophrenia
|
